Skip to content


  • Meeting abstract
  • Open Access

Evidence against a separate high affinity binding site on the P2X3 receptor

  • 1Email author,
  • 1,
  • 2,
  • 2 and
  • 1
BMC Pharmacology20077 (Suppl 2) :A38

  • Published:


  • Binding Site
  • Early Phase
  • Affinity Binding
  • Late Phase
  • P2X3 Receptor

It has been proposed that P2X3 receptors possess a unique mechanism of agonist-induced conformational transitions. Recovery from ATP-induced desensitization was found to be very slow; during this period a special agonist binding site was supposed to be formed which should bind the agonist with high affinity and promote desensitization without activation. The authors supposed that this high affinity binding site is absent from non-activated receptors. The theory was supported by an unexpected outcome of an experiment in which a low concentration of agonist was applied at different phases during recovery from desensitization. The inhibition by a low concentration of agonist was stronger when it was applied during the early phase of recovery when more desensitized receptors were present. The authors used different agonists for initial desensitization and for prolonged perfusion at low concentration. We repeated the experiment on HEK 293 cells expressing human P2X3 receptors with the same results. However, when we used the same agonist at both concentrations the inhibition was stronger when the low concentration was applied during the late phase. Simulations revealed that formation of high affinity binding sites does not require any unique mechanism and can be readily described by an allosteric mechanism. Furthermore, they predict that the unexpected phenomenon can only occur when a rapidly dissociating drug is replaced by a slowly dissociating drug on the receptor.

Authors’ Affiliations

Institute of Experimental Medicine, Budapest, Hungary
Rudolf Boehm Institute of Pharmacology and Toxicology, Leipzig, Germany


© Karoly et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd.